Shell Companies
Compare Stocks
2 / 10Stock Comparison
DMAA vs PFE
Revenue, margins, valuation, and 5-year total return — side by side.
Drug Manufacturers - General
DMAA vs PFE — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Shell Companies | Drug Manufacturers - General |
| Market Cap | $111M | $146.02B |
| Revenue (TTM) | $0.00 | $63.31B |
| Net Income (TTM) | $6M | $7.49B |
| Gross Margin | — | 69.3% |
| Operating Margin | — | 23.4% |
| Forward P/E | — | 8.7x |
| Total Debt | $662.00 | $67.42B |
| Cash & Equiv. | $1K | $1.14B |
DMAA vs PFE — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Feb 25 | May 26 | Return |
|---|---|---|---|
| Drugs Made In Ameri… (DMAA) | 100 | 106.3 | +6.3% |
| Pfizer Inc. (PFE) | 100 | 97.1 | -2.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: DMAA vs PFE
Each card shows where this stock fits in a portfolio — not just who wins on paper.
DMAA is the clearest fit if your priority is sleep-well-at-night and defensive.
- Lower volatility, beta 0.00, current ratio 6.27x
- Beta 0.00, current ratio 6.27x
PFE carries the broadest edge in this set and is the clearest fit for long-term compounding.
- 28.5% 10Y total return vs DMAA's 6.4%
- 6.7% yield; 15-year raise streak; the other pay no meaningful dividend
- +21.1% vs DMAA's +5.0%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Dividends | 6.7% yield; 15-year raise streak; the other pay no meaningful dividend | |
| Momentum (1Y) | +21.1% vs DMAA's +5.0% | |
| Efficiency (ROA) | 3.6% ROA vs DMAA's 2.4% |
DMAA vs PFE — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
DMAA vs PFE — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
Insufficient data to determine a leader in this category.
Income & Cash Flow (Last 12 Months)
PFE and DMAA operate at a comparable scale, with $63.3B and $0 in trailing revenue.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $0 | $63.3B |
| EBITDAEarnings before interest/tax | -$726,546 | $21.0B |
| Net IncomeAfter-tax profit | $6M | $7.5B |
| Free Cash FlowCash after capex | -$414,132 | $9.5B |
| Gross MarginGross profit ÷ Revenue | — | +69.3% |
| Operating MarginEBIT ÷ Revenue | — | +23.4% |
| Net MarginNet income ÷ Revenue | — | +11.8% |
| FCF MarginFCF ÷ Revenue | — | +15.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +5.4% |
| EPS Growth (YoY)Latest quarter vs prior year | — | -9.5% |
Valuation Metrics
Evenly matched — DMAA and PFE each lead in 1 of 2 comparable metrics.
Valuation Metrics
On an enterprise value basis, PFE's 10.4x EV/EBITDA is more attractive than DMAA's 9999.0x.
| Metric | ||
|---|---|---|
| Market CapShares × price | $111M | $146.0B |
| Enterprise ValueMkt cap + debt − cash | $111M | $212.3B |
| Trailing P/EPrice ÷ TTM EPS | -189.29x | 18.88x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 8.66x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 9999.00x | 10.44x |
| Price / SalesMarket cap ÷ Revenue | — | 2.33x |
| Price / BookPrice ÷ Book value/share | — | 1.68x |
| Price / FCFMarket cap ÷ FCF | — | 16.09x |
Profitability & Efficiency
Evenly matched — DMAA and PFE each lead in 2 of 4 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), PFE scores 7/9 vs DMAA's 3/9, reflecting strong financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | — | +8.3% |
| ROA (TTM)Return on assets | +2.4% | +3.6% |
| ROICReturn on invested capital | — | +7.5% |
| ROCEReturn on capital employed | — | +9.0% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 7 |
| Debt / EquityFinancial leverage | — | 0.78x |
| Net DebtTotal debt minus cash | $661 | $66.3B |
| Cash & Equiv.Liquid assets | $1,351 | $1.1B |
| Total DebtShort + long-term debt | $662 | $67.4B |
| Interest CoverageEBIT ÷ Interest expense | — | 4.02x |
Total Returns (Dividends Reinvested)
Evenly matched — DMAA and PFE each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in DMAA five years ago would be worth $10,643 today (with dividends reinvested), compared to $8,517 for PFE. Over the past 12 months, PFE leads with a +21.1% total return vs DMAA's +5.0%. The 3-year compound annual growth rate (CAGR) favors DMAA at 2.1% vs PFE's -6.9% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +2.1% | +5.4% |
| 1-Year ReturnPast 12 months | +5.0% | +21.1% |
| 3-Year ReturnCumulative with dividends | +6.4% | -19.4% |
| 5-Year ReturnCumulative with dividends | +6.4% | -14.8% |
| 10-Year ReturnCumulative with dividends | +6.4% | +28.5% |
| CAGR (3Y)Annualised 3-year return | +2.1% | -6.9% |
Risk & Volatility
DMAA leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
DMAA is the less volatile stock with a 0.00 beta — it tends to amplify market swings less than PFE's 0.49 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DMAA currently trades 100.0% from its 52-week high vs PFE's 89.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.00x | 0.49x |
| 52-Week HighHighest price in past year | $10.60 | $28.75 |
| 52-Week LowLowest price in past year | $10.09 | $21.97 |
| % of 52W HighCurrent price vs 52-week peak | +100.0% | +89.3% |
| RSI (14)Momentum oscillator 0–100 | 71.1 | 43.9 |
| Avg Volume (50D)Average daily shares traded | 166K | 33.3M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
PFE is the only dividend payer here at 6.69% yield — a key consideration for income-focused portfolios.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold |
| Price TargetConsensus 12-month target | — | $27.40 |
| # AnalystsCovering analysts | — | 39 |
| Dividend YieldAnnual dividend ÷ price | — | +6.7% |
| Dividend StreakConsecutive years of raises | — | 15 |
| Dividend / ShareAnnual DPS | — | $1.72 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
DMAA leads in 1 of 6 categories — strongest in Risk & Volatility. 3 categories are tied.
DMAA vs PFE: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is DMAA or PFE a better buy right now?
Pfizer Inc.
(PFE) offers the better valuation at 18. 9x trailing P/E (8. 7x forward), making it the more compelling value choice. Analysts rate Pfizer Inc. (PFE) a "Hold" — based on 39 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — DMAA or PFE?
Over the past 5 years, Drugs Made In America Acquisition Corp.
Ordinary Shares (DMAA) delivered a total return of +6. 4%, compared to -14. 8% for Pfizer Inc. (PFE). Over 10 years, the gap is even starker: PFE returned +28. 5% versus DMAA's +6. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — DMAA or PFE?
By beta (market sensitivity over 5 years), Drugs Made In America Acquisition Corp.
Ordinary Shares (DMAA) is the lower-risk stock at 0. 00β versus Pfizer Inc. 's 0. 49β — meaning PFE is approximately Infinity% more volatile than DMAA relative to the S&P 500.
04Which has better profit margins — DMAA or PFE?
Pfizer Inc.
(PFE) is the more profitable company, earning 12. 4% net margin versus 0. 0% for Drugs Made In America Acquisition Corp. Ordinary Shares — meaning it keeps 12. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PFE leads at 24. 7% versus 0. 0% for DMAA. At the gross margin level — before operating expenses — PFE leads at 70. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — DMAA or PFE?
In this comparison, PFE (6.
7% yield) pays a dividend. DMAA does not pay a meaningful dividend and should not be held primarily for income.
06Is DMAA or PFE better for a retirement portfolio?
For long-horizon retirement investors, Pfizer Inc.
(PFE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 49), 6. 7% yield). Both have compounded well over 10 years (PFE: +28. 5%, DMAA: +6. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between DMAA and PFE?
These companies operate in different sectors (DMAA (Financial Services) and PFE (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: DMAA is a small-cap quality compounder stock; PFE is a mid-cap income-oriented stock. PFE pays a dividend while DMAA does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.
Compare PFE vs JNJ
JNJ is one of the most direct listed alternatives to PFE.
Compare DMAA vs HCAI
HCAI overlaps with DMAA in an adjacent operating segment worth comparing.
Expand With MRK + ABBV
MRK and ABBV are the strongest missing peers across the current compare set.